

## Reference list

# Tumor immunology

## Translational research

### Human T cells

Aissi-Rothé, L. *et al.* (2010) Rapid generation of full clinical-grade human antiadenovirus cytotoxic T cells for adoptive immunotherapy. *J. Immunother.* 33: 414–424.

Feuchtinger, T. *et al.* (2010) Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. *Blood* 116: 4360–4367.

Moosmann, A. *et al.* (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. *Blood* 115: 2960–2970

Prieto, P. A. *et al.* (2010) Enrichment of CD8<sup>+</sup> cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. *J. Immunother.* 33: 547–556.

Wölfel, M. *et al.* (2010) Primed tumor-reactive multifunctional CD62L<sup>+</sup> human CD8<sup>+</sup> T cells for immunotherapy. *Cancer Immunol. Immunother.* Epub ahead of print, Oct 24.

Yang, S. *et al.* (2010) A simplified method for the clinical-scale generation of central memory-like CD8<sup>+</sup> T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. *J. Immunother.* 33: 648–658.

Zandvliet, M. L. *et al.* (2010) Co-ordinated isolation of CD8<sup>+</sup> and CD4<sup>+</sup> T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. *Cytotherapy* 12: 933–944.

Dodero, A. *et al.* (2009) Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. *Blood* 113: 4771–4779.

Kochenderfer, J. *et al.* (2009) Construction and pre-clinical evaluation of an anti-CD19 chimeric antigen receptor. *J. Immunother.* 32: 689–702.

Fujita, Y. *et al.* (2008) Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. *J. Immunother.* 31: 665–674.

Tramsen, L. *et al.* (2008) Clinical-scale generation of human anti-*Aspergillus* T cells for adoptive immunotherapy. *Bone Marrow Transplant.* 43: 13–19.

Wehler, T. *et al.* (2007) Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from anti-leukemic and antitumor donor T-cell lines. *Blood* 109: 365–373.

Nishikawa, H. *et al.* (2006) Influence of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells on low/high-avidity CD4<sup>+</sup> T cells following peptide vaccination. *J. Immunol.* 176: 6340–6346.

Yang, Z. *et al.* (2006) Intratumoral CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cell-mediated suppression of infiltrating CD4<sup>+</sup> T cells in B cell non-Hodgkin lymphoma. *Blood* 107: 3639–3646.

Zhang, Y. *et al.* (2005) Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein. *J. Immunol.* 174: 2404–2411.

Zhao, Y. *et al.* (2005) Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. *J. Immunol.* 174: 4415–4423.

### Human NK cells

Huenecke, S. *et al.* (2010) IL-2 driven regulation of NK cell receptors with regard to the distribution of CD16<sup>+</sup> and CD16<sup>-</sup> subpopulations and *in vivo* influence after haploidentical NK cell infusion. *J. Immunother.* 33: 200–210.

Perez-Martinez, A. *et al.* (2010) KIR–HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. *Pediatr. Blood Cancer* 53: 120–124.

Rubnitz, J. E. *et al.* (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. *J. Clin. Oncol.* 20: 955–959.

#### **Human dendritic cells and B cells**

Di Nicola, M. *et al.* (2009) Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. *Blood* 113: 18–27.

Purbhoo, M. A. *et al.* (2006) Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. *J. Immunol.* 176: 7308–7316.

#### **Mouse dendritic cells**

Bot, A. *et al.* (2006) Immunologic control of tumors by *in vivo* Fcγ receptor–targeted antigen loading in conjunction with doublestranded RNA-mediated immune modulation. *J. Immunol.* 176: 1363–1374.

Dolan, B. P. *et al.* (2006) Tumor-specific CD4<sup>+</sup> T cells are activated by “cross-dressed” dendritic cells presenting peptide–MHC class II complexes acquired from cell-based cancer vaccines. *J. Immunol.* 176: 1447–1455.

Guiducci, C. *et al.* (2005) Redirecting *in vivo* elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. *Cancer Res.* 65: 3437–3446.

Hanks, B. A. *et al.* (2005) Re-engineered CD40 receptor enables potent pharmacological activation of dendritic cell cancer vaccines *in vivo*. *Nat. Med.* 11: 130–137.

## **Basic research**

#### **Human T cells**

Ebert, L. M. *et al.* (2006) Homing and function of human skin γδ T cells and NK cells: Relevance for tumor surveillance. *J. Immunol.* 176: 4331–4336.

Nishikawa, H. *et al.* (2005) CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells control the induction of antigen-specific CD4<sup>+</sup> helper T cell responses in cancer patients. *Blood* 106: 1008–1011.

Goodyear, O. *et al.* (2005) CD8<sup>+</sup> T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. *Blood* 106: 4217–4224.

#### **Human NK cells**

Castriconi, R. *et al.* (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. *J. Immunol.* 182: 3530–3539.

Fauriat, C. *et al.* (2007) Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCR<sup>dull</sup> phenotype induction. *Blood* 109: 323–330.

#### **Human dendritic cells/monocytes**

Chauhan, D. *et al.* (2009) Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. *Cancer Cell* 16: 309–323.

Fiore, F. *et al.* (2006) Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L. *Leuk. Lymphoma* 47: 613–622.

Hagemann, T. *et al.* (2006) Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. *J. Immunol.* 176: 5023–5032.

Kukreja, A. *et al.* (2006) Enhancement of clonogenicity of human multiple myeloma by dendritic cells. *J. Exp. Med.* 203: 1859–1865.

Li, H. *et al.* (2006) IFN-γ and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK1/2–dependent and IL-12–independent pathways. *J. Immunol.* 177: 3554–3563.

Maecker, B. *et al.* (2006) Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. *Leukemia* 20: 645–649.

Popov, A. *et al.* (2006) Indoleamine 2, 3-dioxygenase-expressing dendritic cells form suppurative granulomas following *Listeria monocytogenes* infection. *J. Clin. Invest.* 116: 3160–3170.

von Bergwelt-Baildon, M. S. *et al.* (2006) CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E<sub>2</sub> and expressed by tumor-associated dendritic cells *in vivo*: additional mechanisms of T cell inhibition. *Blood* 108: 228–237.

del Fresno, C. *et al.* (2005) Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase - M expression via CD44 and TLR 4. *J. Immunol.* 174: 3032–3040.

Neumann, F. *et al.* (2005) Identification of an epitope derived from the cancer testis antigen HOM-TE5-14/SCP1 and presented by dendritic cells to circulating CD4<sup>+</sup> T cells. *Blood* 106: 3105–3113.

Schnurr, M. *et al.* (2005) Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. *Blood* 105: 2465–2472.

#### **Human B cells/plasma cells**

Chen, L. *et al.* (2010) Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. *Blood* 115: 61–70.

Morin, R. D. *et al.* (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nature Genetics* 42: 181–185.

Jones, R. J. *et al.* (2009) Circulating clonotypic B cells in classic Hodgkin lymphoma. *Blood* 113: 5920–5926.

Kukreja, A. *et al.* (2006) Enhancement of clonogenicity of human multiple myeloma by dendritic cells.

*J. Exp. Med.* 203: 1859–1865.

Piovan, E. *et al.* (2005) Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. *Blood* 105: 931–939.

### Mouse T cells

Burckhart, T. *et al.* (2010) Tumor-specific crosslinking of GITR as costimulation for immunotherapy. *J. Immunother.* 33: 925–934.

Koneru, M. *et al.* (2006) Defective adhesion in tumor infiltrating CD8<sup>+</sup> T cells. *J. Immunol.* 176: 6103–6111.

Ramirez-Montagut, T. *et al.* (2006) Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.

*J. Immunol.* 176: 6434–6442.

Nishikawa, H. *et al.* (2005) Accelerated chemically induced tumor development mediated by CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells in wild type hosts. *Proc. Natl. Acad. Sci. USA* 102: 9253–9257.

Yu, P. *et al.* (2005) Intratumor depletion of CD4<sup>+</sup> cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. *J. Exp. Med.* 201: 779–791.

### Mouse NK cells

Lundqvist, A. *et al.* (2009) Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. *Blood* 113: 6120–6127.

Fan, Z. *et al.* (2006) NK-cell activation by LIGHT triggers tumor-specific CD8<sup>+</sup> T cell immunity to reject established tumors. *Blood* 107: 1342–1351.

### Mouse dendritic cells

McDonnell, A. M. *et al.* (2010) CD8a1 DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. *Eur. J. Immunol.* 40: 1617–1627.

Qu, Y. *et al.* (2010) Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. *J. Immunol.* 185: 2895–2902.

den Brok, M. *et al.* (2006) Synergy between *in situ* cryoablation and TLR9 stimulation results in a highly effective *in vivo* dendritic cell vaccine. *Cancer Res.* 66: 7285–7292.

Preynat-Seauve, O. *et al.* (2006) Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. *J. Immunol.* 176: 61–67.

### Mouse B cells and other cells

Ko, H.-J. (2009) Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. *J. Immunol.* 182: 1818–1828.

Zeng, Y. *et al.* (2007) Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. *Cancer Res.* 67: 2331–2338.

Shimizu, K. *et al.* (2007) Tumor cells loaded with  $\alpha$ -galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. *J. Immunol.* 178: 2853–2861.



### Miltenyi Biotec

**Miltenyi Biotec GmbH**  
Friedrich-Ebert-Straße 68  
51429 Bergisch Gladbach  
Germany  
Phone +49 2204 8306-0  
Fax +49 2204 85197  
macs@miltenyibiotec.de

**Miltenyi Biotec Inc.**  
2303 Lindbergh Street  
Auburn, CA 95602-9562, USA  
Phone 800 FOR MACS  
Phone +1 530 888 8871  
Fax +1 530 888 8925  
macs@miltenyibiotec.com

**Miltenyi Biotec B.V. (Benelux)**  
macs@miltenyibiotec.nl  
**Customer service Netherlands**  
Phone 0800 4020120  
**Customer service Belgium**  
Phone 0800 94016  
**Customer service Luxembourg**  
Phone 800 24971

**Miltenyi Biotec SAS (France)**  
Phone +33 1 56 98 16 16  
macs@miltenyibiotec.fr

**Miltenyi Biotec S.r.l. (Italy)**  
Phone +39 051 646 0411  
macs@miltenyibiotec.it

**Miltenyi Biotec K.K. (Japan)**  
Phone +81 3 5646 8910  
macs@miltenyibiotec.jp

**Miltenyi Biotec Asia Pacific Pte. Ltd. (Singapore)**  
Phone +65 6238 8183  
macs@miltenyibiotec.com.sg

**Miltenyi Biotec S.L. (Spain)**  
Phone +34 91 512 12 90  
macs@miltenyibiotec.es

**Miltenyi Biotec Ltd. (UK)**  
Phone +44 1483 799 800  
macs@miltenyibiotec.co.uk

[www.miltenyibiotec.com](http://www.miltenyibiotec.com)

**Miltenyi Biotec Australia Pty. Ltd.**  
Phone +61 2 8877 7400  
macs@miltenyibiotec.com.au

**Miltenyi Biotec Trading (Shanghai) Co., Ltd. (P.R. China)**  
Phone +86 21 6235 1005  
macs@miltenyibiotec.com.cn

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS and the MACS logo are registered trademarks of Miltenyi Biotec GmbH.